Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCSD
Dates
study started
completion around

Description

Summary

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Official Title

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4

Keywords

Multiple Myeloma, Maintenance, Teclistamab, Plasma Cell Neoplasms, Lenalidomide, Teclistamab-Lenalidomide (Tec-Len)

Eligibility

Locations

  • University of California-Davis Cancer Center not yet accepting patients
    Sacramento California 95817 United States
  • University of California, San Diego (UCSD) Medical Center not yet accepting patients
    San Diego California 92093 United States
  • Saskatoon Cancer Center accepting new patients
    Saskatoon Canada
  • Princess Margaret Cancer Centre accepting new patients
    Toronto Canada

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Stichting European Myeloma Network
ID
NCT05243797
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 1594 study participants
Last Updated